Skip to main content

Table 2 Patients characteristics

From: Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity

  

RTH dose prescribed

 

Characteristics

All

(n = 277,100%)

70Gy

(n = 30, 10.8%)

74Gy

(n = 177, 63.9%)

80Gy

(n = 70, 25.3%)

p-value

Age (years)

69 (51–79)

70 (56;79)

71 (51;79)

68.5 (51;76)

0.03

Follow up (months)

53.1 (3.4–150)

48.4 (3.9;94.8)

47.1 (3.4;150.2)

75.6 (7.8;131.7)

<0.01

PSA level (ng/ml)

 <10

166 (59.9%)

26 (86.7%)

105 (59.4%)

35 (50%)

<0.01

 10–20

79 (28.5%)

3 (10%)

19 (10.7%)

10 (14.3%)

 >20

32 (11.6%)

1 (3.3%)

53 (29.9%)

25 (35.7%)

Gleason

 6

88 (32.1%)

23 (76.7%)

46 (26.3%)

19 (27.5%)

<0.01

 7 (3 + 4)

84 (30.7%)

4 (13.3%)

52 (29.7%)

28 (40.6%)

 7 (4 + 3)

60 (21.9%)

1 (3.3%)

47 (26.9%)

12 (17.4%)

 8–10

42 (15.3%)

2 (6.7%)

30 (17.1%)

10 (14.5%)

Tumor stage

 T1-T2a

178 (64.3%)

25 (83.3%)

110 (62.2%)

43 (61.4%)

0.15

 T2b

44 (15.9%)

3 (10%)

27 (15.3%)

14 (20%)

 T2c-T4

55 (19.9%)

2 (6.7%)

40 (22.5%)

13 (18.6%)

D’Amico risk group

 Low risk

41 (14.8%)

20 (66.7%)

20 (11.3%)

1 (1.4%)

<0.01

 Intermediate risk

161 (58.1%)

7 (23.3%)

103 (58.2%)

51 (72.9%)

 High risk

75 (27.1%)

3 (10%)

54 (30.5%)

18 (25.7%)

Androgen deprivation

 No

149 (53.9%)

23 (76.7%)

90 (50.9%)

36 (51.4%)

0.03

 Yes

128 (46.1%)

7 (23.3%)

87 (49.1%)

34 (48.6%)

  Short (< 6 months)

70 (25.4%)

4 (13.3%)

38 (21.7%)

28 (40%)

<0.01

  Long (> 6 months)

57 (20.7%)

3 (10%)

48 (27.4%)

6 (8.6%)

IPSS baseline

 0–7

236 (85.2%)

24 (80%)

154 (87%)

58 (82.9%)

0.49

 ≥8

41 (14.8%)

6 (20%)

23 (13%)

12 (17.1%)

Diabetes

 Yes

49 (17.9%)

5 (16.7%)

33 (18.9%)

11 (15.9%)

0.85

Coronary disease

 Yes

46 (16.9%)

5 (18.5%)

31 (17.6%)

10 (14.5%)

0.82

High blood pressure

 Yes

151 (54.9%)

18 (60%)

98 (55.7%)

35 (50.7%)

0.66

Surgery

 Abdominal

29 (10.5%)

6 (20%)

17 (9.6%)

6 (8.6%)

0.19

 Pelvic

86 (31.1%)

2 (6.7%)

46 (26%)

38 (54.3%)

<0.01

 Other

46 (16.7%)

7 (23.3%)

28 (15.8%)

11 (15.7%)

0.57

Transurethral resection of prostate

 Yes

38 (13.8%)

20% (6)

14.29% (25)

10% (7)

0.40

Alpha blocker treatment at D-1 RTH

 Yes

57 (20.7%)

6 (20%)

44 (25.1%)

11 (15.7%)

0.26

Anticoagulant or antiplatelet treatment

 Yes

112 (40.7%)

11 (36.7%)

78 (44.6%)

23 (32.9%)

0.21

  1. Qualitative parameters are described with frequency and percentage; quantitative parameters with median and range
  2. Abbreviations: PSA prostate specific antigen, risk group D’Amico classification, IPSS International Prostate Score Symptom, RTH radiotherapy, D-1 day one of treatment